衛星コネクティビティの世界市場（2024年版）：コンポーネント別（ビデオ、固定、モビリティ）、タイプ別、最終用途別、地域別、国別の分析：市場インサイトと予測（2020-2030年）

Global Satellite Connectivity Market (2024 Edition): Analysis By Component (Video, Fixed, Mobility), By Type, By End-use, By Region, By Country: Market Insights and Forecast (2020-2030)

エグゼクティブ・サマリー Azoth Analytics社はこのたび、「免疫性血小板減少症治療薬の世界市場（2024年版）」と題する調査報告書を発表しました。この調査報告書では、免疫性血小板減少症治療薬の世界市場に... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2024年4月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	252	英語

サマリー

エグゼクティブ・サマリー

Azoth Analytics社はこのたび、「免疫性血小板減少症治療薬の世界市場（2024年版）」と題する調査報告書を発表しました。この調査報告書では、免疫性血小板減少症治療薬の世界市場について、治療別（免疫グロブリン静注、2019-2022年の過去期間、2023年の予測期間、2024-2029年の予測期間について、治療法別（トロンボポエチン受容体作動薬、副腎皮質ステロイド、その他）、タイプ別（急性、慢性）、エンドユーザー別（病院・クリニック、専門センター、研究・学術機関）を掲載しています。

当レポートでは、免疫性血小板減少症治療薬市場を地域別（南北アメリカ、ヨーロッパ、アジア太平洋地域、中東・アフリカ）および10カ国別（米国、カナダ、英国、ドイツ、フランス、スペイン、中国、日本、韓国、インド）に分析しています。世界の免疫性血小板減少症治療薬市場は2019-2022年にCAGR 21.32%の成長を示した。2022年の市場規模は3億6,614万ドルで、2029年には1億2,308万7,000ドルに達すると予測される。免疫性血小板減少症治療薬市場は、世界的な免疫性血小板減少症の有病率の上昇がITP治療薬市場の重要な推進力となっている。人口の高齢化、疾患に対する認識と診断の向上、自己免疫疾患の罹患率の増加といった要因がITPの負担増に寄与し、効果的な治療薬への需要を促進している。

National Centre for Biotechnology Informationによると、免疫性血小板減少症（ITP）は10万患者年あたり1.6〜3.9人の罹患率で発症する。患者数の増加は市場の可能性の拡大につながり、研究開発、マーケティング、販売活動への投資を促進する。製薬会社は、ITPの有病率の上昇によって拡大する市場機会を活用するため、ITP治療薬の開発イニシアチブを優先する可能性がある。

また、National Organization of Rare Diseaseによると、米国では、ITPの年間発症率は人口10万人あたり約3.3人と推定されている3。ヨーロッパにおけるITPの有病率の増加は、ITP治療薬の研究開発を刺激している。これらの地域の製薬会社は、ITP治療薬に対する需要の高まりに応え、さまざまな地域でITP患者のニーズに対応する薬剤を開発・販売している。

新しい薬物送達技術により、ITP治療薬の投与と効果が向上している。長時間作用型製剤、皮下注射、経口製剤は、従来の静脈内治療と比較して、利便性の向上、投与回数の減少、患者の服薬アドヒアランスの向上をもたらしています。このような薬物送達技術の進歩により、ITP管理における患者の快適性と治療コンプライアンスが向上しています。

TPO-RAの進歩により、有効性と安全性が改善された新薬が開発されている。アバトロンボパグやルスツトロンボパグなどの第2世代TPO-RAは、ロミプロスチムやエルトロンボパグなどの初期の薬剤と比較して、優れた血小板反応率と副作用の軽減を実証している。これらの進歩により、ITP患者の治療選択肢は拡大し、治療成績も改善した。

病院や診療所では、ITPの正確でタイムリーな診断を促進するために、高度な診断技術を採用している。フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、遺伝子検査などの技術により、ITP患者の免疫調節異常、自己抗体、遺伝的素因を検出することができます。高度な診断技術により、医療従事者は一次性ITPと二次性血小板減少症の原因を鑑別することができ、治療方針の決定や患者の転帰の改善に役立てることができる。

技術の進歩は、世界の免疫性血小板減少症治療薬市場における技術革新と進歩を促進し、創薬、開発、製造、臨床診療を加速させます。これらの進歩により、バイオマーカー探索、ハイスループットスクリーニング、計算モデリング、バイオ医薬品製造、ドラッグデリバリーシステム、デジタルヘルス技術が強化され、世界中の患者にとってITP治療の有効性、安全性、利用しやすさが向上します。

報告書の範囲

- 本レポートでは、免疫性血小板減少症治療薬市場を金額（百万米ドル）別に分析しています。

- 免疫性血小板減少症治療薬市場をパイプラインシナリオ別に分析しています。

- 免疫性血小板減少症治療薬市場を地域別（南北アメリカ、ヨーロッパ、アジア太平洋、中東・アフリカ）、10カ国別（アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、中国、日本、韓国、インド）に分析しています。

- 本レポートでは、免疫性血小板減少症治療薬市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介します。

- 免疫性血小板減少症治療薬市場を治療薬別（免疫グロブリン静注、トロンボポエチン受容体作動薬、副腎皮質ステロイド、その他）に分析しています。

- 免疫性血小板減少症治療薬市場をタイプ別（急性、慢性）に分析しています。

- 免疫性血小板減少症治療薬市場をエンドユーザー別（病院・クリニック、専門センター、研究・学術機関）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、治療別、タイプ別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 競合の動向、戦略、M&A、新製品開発についても追跡しています。本レポートで分析対象とした企業は、CSLベーリング、ライジェルファーマシューティカルズ、ノバルティス、ファイザー、テバ・ファーマシューティカルズ、サノフィ、アムジェン、グリフォルス、武田薬品工業、インタスファーマシューティカルズなどです。

ページTOPに戻る

Table of Content

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

2.1 Amplify development of intravenous drugs for chronic application

2.2 Escalate collaboration initiative with healthcare provider

3. Global Immune Thrombocytopenia Drug Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Global Immune Thrombocytopenia Drug Market

3.2 Pipeline Scenario

3.3 Frequency of adult secondary Immune Thrombocytopenia

3.4 Global Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

3.5 Degree of Impact of Covid-19 on Immune Thrombocytopenia Drug Market

3.6 Global Immune Thrombocytopenia Drug Market Segmentation: By Treatment

3.6.1 Global Immune Thrombocytopenia Drug Market, By Treatment Overview

3.6.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Treatment Overview

3.6.3 Global Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)

3.6.4 Global Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)

3.6.5 Global Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)

3.6.6 Global Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

3.7 Global Immune Thrombocytopenia Drug Market Segmentation: By Type

3.7.1 Global Immune Thrombocytopenia Drug Market, By Type Overview

3.7.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Type Overview

3.7.3 Global Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

3.7.4 Global Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)

3.8 Global Immune Thrombocytopenia Drug Market Segmentation: By End-User

3.8.1 Global Immune Thrombocytopenia Drug Market, By End-User Overview

3.8.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By End-User Overview

3.8.3 Global Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)

3.8.4 Global Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)

3.8.5 Global Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Immune Thrombocytopenia Drug Market, Region Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Immune Thrombocytopenia Drug Market: Historic and Forecast

5.1 Americas Immune Thrombocytopenia Drug Market: Snapshot

5.2 Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.3 Americas Immune Thrombocytopenia Drug Market: Key Factors

5.4 Americas Immune Thrombocytopenia Drug Market: Segment Analysis

5.5 Americas Immune Thrombocytopenia Drug Market Segmentation: By Treatment

5.5.1 Americas Immune Thrombocytopenia Drug Market, By Treatment Overview

5.5.2 Americas Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)

5.5.3 Americas Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)

5.5.4 Americas Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)

5.5.5 Americas Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

5.6 Americas Immune Thrombocytopenia Drug Market Segmentation: By Type

5.6.1 Americas Immune Thrombocytopenia Drug Market, By Type Overview

5.6.2 Americas Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

5.6.3 Americas Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)

5.7 Americas Immune Thrombocytopenia Drug Market Segmentation: By End-User

5.7.1 Americas Immune Thrombocytopenia Drug Market, By End-User Overview

5.2.2 Americas Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)

5.7.3 Americas Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)

5.7.4 Americas Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)

5.8 Americas Immune Thrombocytopenia Drug Market Segmentation: By Country

5.8.1 Americas Immune Thrombocytopenia Drug Market, By Country Overview

5.8.2 United States Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.8.2.1 United States Immune Thrombocytopenia Drug Market, By Treatment

5.8.2.2 United States Immune Thrombocytopenia Drug Market, By Type

5.8.2.3 United States Immune Thrombocytopenia Drug Market, By End-User

5.8.3 Canada Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.8.3.1 Canada Immune Thrombocytopenia Drug Market, By Treatment

5.8.3.2 Canada Immune Thrombocytopenia Drug Market, By Type

5.8.3.3 Canada Immune Thrombocytopenia Drug Market, By End-User

5.10.4 Rest of Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.10.4.1 Rest of Americas Immune Thrombocytopenia Drug Market, By Treatment

5.10.4.2 Rest of Americas Immune Thrombocytopenia Drug Market, By Type

5.10.4.3 Rest of Americas Immune Thrombocytopenia Drug Market, By End-User

6. Europe Immune Thrombocytopenia Drug Market: Historic and Forecast

6.1 Europe Immune Thrombocytopenia Drug Market: Snapshot

6.2 Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.3 Europe Immune Thrombocytopenia Drug Market: Key Factors

6.4 Europe Immune Thrombocytopenia Drug Market: Segment Analysis

6.5 Europe Immune Thrombocytopenia Drug Market Segmentation: By Treatment

6.5.1 Europe Immune Thrombocytopenia Drug Market, By Treatment Overview

6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)

6.5.5 Europe Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

6.6 Europe Immune Thrombocytopenia Drug Market Segmentation: By Type

6.6.1 Europe Immune Thrombocytopenia Drug Market, By Type Overview

6.6.2 Europe Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

6.6.3 Europe Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)

6.7 Europe Immune Thrombocytopenia Drug Market Segmentation: By End-User

6.7.1 Europe Immune Thrombocytopenia Drug Market, By End-User Overview

6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)

6.8 Europe Immune Thrombocytopenia Drug Market Segmentation: By Country

6.8.1 Europe Immune Thrombocytopenia Drug Market, By Country Overview

6.8.2 United Kingdom Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.2.1 United Kingdom Immune Thrombocytopenia Drug Market, By Treatment

6.8.2.2 United Kingdom Immune Thrombocytopenia Drug Market, By Type

6.8.2.3 United Kingdom Immune Thrombocytopenia Drug Market, By End-User

6.8.3 Germany Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.3.1 Germany Immune Thrombocytopenia Drug Market, By Treatment

6.8.3.2 Germany Immune Thrombocytopenia Drug Market, By Type

6.8.3.3 Germany Immune Thrombocytopenia Drug Market, By End-User

6.8.4 France Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.4.1 France Immune Thrombocytopenia Drug Market, By Treatment

6.8.4.2 France Immune Thrombocytopenia Drug Market, By Type

6.8.4.3 France Immune Thrombocytopenia Drug Market, By End-User

6.8.5 Spain Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.5.1 Spain Immune Thrombocytopenia Drug Market, By Treatment

6.8.5.2 Spain Immune Thrombocytopenia Drug Market, By Type

6.8.5.3 Spain Immune Thrombocytopenia Drug Market, By End-User

6.8.6 Rest of Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.6.1 Rest of Europe Immune Thrombocytopenia Drug Market, By Treatment

6.8.6.2 Rest of Europe Immune Thrombocytopenia Drug Market, By Type

6.8.6.3 Rest of Europe Immune Thrombocytopenia Drug Market, By End-User

7. Asia Pacific Immune Thrombocytopenia Drug Market: Historic and Forecast

7.1 Asia Pacific Immune Thrombocytopenia Drug Market: Snapshot

7.2 Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.3 Asia Pacific Immune Thrombocytopenia Drug Market: Key Factors

7.4 Asia Pacific Immune Thrombocytopenia Drug Market: Segment Analysis

7.5 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Treatment

7.5.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment Overview

7.5.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)

7.5.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)

7.5.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)

7.5.5 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

7.6 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Type

7.6.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Type Overview

7.6.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

7.6.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)

7.7 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By End-User

7.7.1 Asia Pacific Immune Thrombocytopenia Drug Market, By End-User Overview

7.7.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)

7.7.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)

7.7.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)

7.8 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Country

7.8.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Country Overview

7.8.2 China Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.2.1 China Immune Thrombocytopenia Drug Market, By Treatment

7.8.2.2 China Immune Thrombocytopenia Drug Market, By Type

7.8.2.3 China Immune Thrombocytopenia Drug Market, By End-User

7.8.3 Japan Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.3.1 Japan Immune Thrombocytopenia Drug Market, By Treatment

7.8.3.2 Japan Immune Thrombocytopenia Drug Market, By Type

7.8.3.3 Japan Immune Thrombocytopenia Drug Market, By End-User

7.8.4 South Korea Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.4.1 South Korea Immune Thrombocytopenia Drug Market, By Treatment

7.8.4.2 South Korea Immune Thrombocytopenia Drug Market, By Type

7.8.4.3 South Korea Immune Thrombocytopenia Drug Market, By End-User

7.8.5 India Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.5.1 India Immune Thrombocytopenia Drug Market, By Treatment

7.8.5.2 India Immune Thrombocytopenia Drug Market, By Type

7.8.5.3 India Immune Thrombocytopenia Drug Market, By End-User

7.8.6 Rest of Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.6.1 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment

7.8.6.2 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Type

7.8.6.3 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By End-User

8. Middle East and Africa Immune Thrombocytopenia Drug Market: Historic and Forecast

8.1 Middle East and Africa Immune Thrombocytopenia Drug Market: Snapshot

8.2 Middle East and Africa Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

8.3 Middle East and Africa Immune Thrombocytopenia Drug Market: Key Factors

8.4 Middle East and Africa Immune Thrombocytopenia Drug Market: Segment Analysis

8.5 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Treatment

8.5.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Treatment Overview

8.5.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)

8.5.3 Middle East and Africa Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)

8.5.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)

8.5.5 Middle East and Africa Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)

8.6 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Type

8.6.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Type Overview

8.6.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

8.6.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)

8.7 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By End-User

8.7.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By End-User Overview

8.7.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)

8.7.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)

8.7.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact assessment of Market Dynamics on Global Immune Thrombocytopenia Drug Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share of Leading Companies

11.3 Company Profiling

11.3.1 CSL Behring

11.3.2 Rigel Pharmaceuticals

11.4.3 Novartis

11.3.4 Pfizer

11.3.5 Teva Pharmaceutical

11.3.6 Sanofi

11.3.7 Amgen, Inc.

11.3.8 Grifols

11.3.9 Takeda Pharmaceuticals

11.3.10 Intas Pharmaceuticals

12. About Us and Disclaimer

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global Immune Thrombocytopenia Drug Market (2024 Edition)” which provides a complete analysis of the Global Immune Thrombocytopenia Drug industry in terms of market segmentation By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type (Acute, Chronic), By End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India). The Global Immune Thrombocytopenia Drug market showcased growth at a CAGR of 21.32% during 2019-2022. The market was valued at USD 3661.45 Million in 2022 which is expected to reach USD 12308.37 Million in 2029. Immune Thrombocytopenia Drug Market is being propelled by rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.

According to National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years, The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in research and development, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition.

Also, According to National Organization of Rare Disease, In the United States, the annual incidence of ITP is estimated around 3.3 per 100,000 people.3 In Europe, the annual incidence of ITP among adults is estimated at around 1 to 4 per 100,000 people. The growing prevalence of ITP in the has stimulated research and development efforts in the field of ITP drugs. Pharmaceutical companies in these regions have responded to the growing demand for ITP treatments by developing and marketing drugs to address the needs of patients with this condition across different geographic areas.

Novel drug delivery technologies have enhanced the administration and effectiveness of ITP medications. Long-acting formulations, subcutaneous injections, and oral formulations offer improved convenience, reduced dosing frequency, and enhanced patient adherence compared to traditional intravenous therapies. These advancements in drug delivery technology have improved patient comfort and treatment compliance in ITP management.

Advancements in TPO-RAs have led to the development of new agents with improved efficacy and safety profiles. Second-generation TPO-RAs, such as avatrombopag and lusutrombopag, have demonstrated superior platelet response rates and reduced side effects compared to earlier agents like romiplostim and eltrombopag. These advancements have expanded treatment options for patients with ITP and improved treatment outcomes.

Hospitals and clinics have adopted advanced diagnostic technologies to facilitate accurate and timely diagnosis of ITP. Techniques such as flow cytometry, polymerase chain reaction (PCR), and genetic testing allow for the detection of immune dysregulation, autoantibodies, and underlying genetic predispositions in patients with ITP. Advanced diagnostic technologies enable healthcare providers to differentiate primary ITP from secondary causes of thrombocytopenia, guiding treatment decisions and improving patient outcomes.

Technological advancements drive innovation and progress in the global Immune Thrombocytopenia Drug Market, accelerating drug discovery, development, manufacturing, and clinical practice. These advancements enhance biomarker discovery, high-throughput screening, computational modeling, biopharmaceutical manufacturing, drug delivery systems, and digital health technologies, improving the efficacy, safety, and accessibility of ITP treatments for patients worldwide.

Scope of the Report:

• The report analyses the Immune Thrombocytopenia Drug Market by Value (USD Million).

• The report analyses the Immune Thrombocytopenia Drug Market by Pipeline Scenario.

• The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India).

• The report presents the analysis of Immune Thrombocytopenia Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Immune Thrombocytopenia Drug Market by Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others).

• The report analyses the Immune Thrombocytopenia Drug Market by Type (Acute, Chronic).

• The report analyses the Immune Thrombocytopenia Drug Market by End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By treatment, by type & by end users.

• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include CSL Behring, Rigel Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceutical, Sanofi, Amgen, Inc., Grifols, Takeda Pharmaceuticals and Intas Pharmaceuticals.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信・IT）の最新刊レポート

Azoth Analytics社の電子機器・技術分野での最新刊レポート

本レポートと同じKEY WORD（video）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

衛星コネクティビティの世界市場（2024年版）：コンポーネント別（ビデオ、固定、モビリティ）、タイプ別、最終用途別、地域別、国別の分析：市場インサイトと予測（2020-2030年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（通信・IT）の最新刊レポート

Azoth Analytics社の電子機器・技術分野での最新刊レポート

本レポートと同じKEY WORD（video）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?